Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wyeth Re-enters Appetite Suppression Game With Thiakis Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Metabolic disorders is one of six focus areas targeted by Wyeth’s new discovery plan.

You may also be interested in...



Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist

Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.

Boehringer Enhances Diabetes Pipeline With Zealand's GLP-1/Glucagon Agonist

Boehringer wins global rights to Zealand's Phase I-ready novel diabetes compound, pledging €20 million during 2011.

Imperial Innovations Raises £140 Million To Invest In University Spin-Outs

The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067144

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel